Abstract
Cytokines are soluble proteins that mediate intercellular signaling regulating immune and inflammatory responses. Cytokine modulation represents a promising cancer immunotherapy approach for immune-mediated tumor regression. However, redundancy in cytokine signaling and cytokines' pleiotropy, narrow therapeutic window, systemic toxicity, short half-life and limited efficacy represent outstanding challenges for cytokine-based cancer immunotherapies. Recently, there has been interest in the paradoxical role of IL-10 in cancer, its controversial prognostic utility and novel strategies to enhance its therapeutic profile. Here, the authors review the literature surrounding the role of IL-10 within the tumor microenvironment, its prognostic correlates to cancer patient outcomes and its pro- and antitumor effects, and they assess the legitimacy of potential therapeutic strategies harnessing IL-10 by outlining the notable preclinical and clinical evidence to date.
Original language | English |
---|---|
Pages (from-to) | 3349-3365 |
Number of pages | 17 |
Journal | Future Oncology |
Volume | 18 |
Issue number | 29 |
Early online date | 29 Sept 2022 |
DOIs | |
Publication status | E-pub ahead of print - 29 Sept 2022 |
Keywords
- Review
- biomarkers
- cancer immunotherapy
- cytokines
- IL-10
- pegilodecakin
- precision medicine
- prognosis
- review
- targeted therapy
- tumor microenvironment